- PII
- S19982860S0132342325050246-1
- DOI
- 10.7868/S1998286025050246
- Publication type
- Article
- Status
- Published
- Authors
- Volume/ Edition
- Volume 51 / Issue number 5
- Pages
- 1001-1008
- Abstract
- Ionizable lipids are a key component of the lipid nanoparticle platform for RNA therapy. They ensure the efficient assembly of a lipid–nucleic acid complex, protect it from premature degradation, and after endocytosis, promote the release of RNA into the cytoplasm for further processing. The paper describes the synthesis of a new ionizable cationic lipid that is a diglyceride derivative of tertiary alkylamine – [5-[1,2-di(decanoyloxy)propane-3-iloxy]pentyl-(4-hydroxybutyl)-amino]pentoxy]-2-decanoyloxypropyl] decanoate (An-1). The synthesis is characterized by the simplicity and cost-effectiveness of reagents. Comparative experiments with the well-known ionizable lipid ALC-0315 have shown that An-1 lipid forms lipid nanoparticles (LNPs) similar in size and incorporation efficiency of the model mRNA. LNPs with mRNA of the green fluorescent protein formulated with An-1 lipid transfected cells in culture more efficiently than LNPs formulated with ALC-0315 lipid. It is assumed that the new ionizable lipid can be used in the production of mRNA vaccines.
- Keywords
- ионизируемый липид синтез липидные наночастицы мРНК
- Date of publication
- 01.05.2025
- Year of publication
- 2025
- Number of purchasers
- 0
- Views
- 4
References
- 1. Cullis P.R., Felgner P.L. // Nat. Rev. Drug Discov. 2024. V. 23. P. 709–722. https://doi.org/10.1038/s41573-024-00977-6
- 2. Han X., Mitchell M.J., Nie G. // Matter. 2020. V. 3. P. 1948–1975. https://doi.org/10.1016/j.matt.2020.09.020
- 3. Han X., Zhang H., Butowska K., Swingle K.L., Alameh M.-G., Weissman D., Mitchell M.J. // Nat. Commun. 2021. V. 12. P. 7233. https://doi.org/10.1038/s41467-021-27493-0
- 4. Semple S.C., Akinc A., Chen J., Sandhu A.P., Mui B.L., Cho C.K., Sah D.W., Stebbing D., Crosley E.J., Yaworski E., Hafez I.M., Dorkin J.R., Qin J., Lam K., Rajeev K.G., Wong K.F., Jeffs L.B., Nechev L., Eisenhardt M.L., Jayaraman M., Kazem M., Maier M.A., Srinivasulu M., Weinstein M.J., Chen Q., Alvarez R., Barros S.A., De S., Klimuk S.K., Borland T., Kosovrasti V., Cantley W.L., Tam Y.K., Manoharan M., Ciufolini M.A., Tracy M.A., de Fougerolles A., Mac-Lachlan I., Cullis P.R., Madden T.D., Hope M.J. // Nat. Biotechnol. 2010. V. 28. P. 172–176. https://doi.org/10.1038/nbt.1602
- 5. Mrksich K., Padilla M.S., Mitchell M.J. // Adv. Drug Deliv. Rev. 2024. V. 214. P. 115446. https://doi.org/10.1016/j.addr.2024.115446
- 6. European Medicines Agency, Comirnaty Assessment Report. COVID-19 mRNA vaccine (nucleoside-modified). https://www.ema.europa.eu/en/documents/assessment-report/comirnaty-epar-public-assessment-report_en.pdf
- 7. Jörgensen A.M., Wibel R., Bernkop-Schnürch A. // Small. 2023. V. 19. P. 2206968. https://doi.org/10.1002/smll.202206968
- 8. Болдырев И.А., Шендриков В.П., Кислова С.О., Потешнова М.В., Андреев Д.Е., Рубцов Ю.П., Рубцова М.П., Водовозова Е.Л. // Патент RU2823298C1, 2024.
- 9. Schoenmaker L., Witzigmann D., Kulkarni J.A., Verbeke R., Kersten G., Jiskoot W., Crommelin D.J.A. // Int. J. Pharm. 2021. V. 601. P. 120586. https://doi.org/10.1016/j.ijpharm.2021.120586
- 10. Cheng X., Lee R.J. // Adv. Drug Deliv. Rev. 2016. V. 99. P. 129–137. https://doi.org/10.1016/j.addr.2016.01.022
- 11. Münter R., Larsen J.B., Andresen T.L. // J. Colloid Interface Sci. 2024. V. 674. P. 139–144. https://doi.org/10.1016/j.jcis.2024.06.158
- 12. Schultz D., Münter R.D., Cantín A.M., Kempen P.J., Jahnke N., Andresen T.L., Simonsen J.B., Urquhart A.J. // Eur. J. Pharm. Biopharm. 2024. V. 205. P. 114571. https://doi.org/10.1016/j.ejpb.2024.114571
- 13. Zalba S., Ten Hagen T.L.M., Burgui C., Garrido M.J. // J. Control. Release. 2022. V. 351. P. 22–36. https://doi.org/10.1016/j.jconrel.2022.09.002
- 14. Fedorovskiy A.G., Antropov D.N., Dome A.S., Puchkov P.A., Makarova D.M., Konopleva M.V., Matveeva A.M., Panova E.A., Shmendel E.V., Maslov M.A., Dmitriev S.E., Stepanov G.A., Markov O.V. // Pharmaceutics. 2024. V. 16. P. 684. https://doi.org/10.3390/pharmaceutics16050684
